×
About 10 results

ALLMedicine™ Anklyosing Spondylitis Center

Research & Reviews  2 results

Prevalence and Clinical Course of Chronic Hep B Infection in IBD and Rheumatologic Disease
https://clinicaltrials.gov/ct2/show/NCT02128503

Apr 24th, 2017 - The incidence of inflammatory bowel disease (IBD) has been increasing in Hong Kong. The management of inflammatory bowel disease involved the use of immunosuppressant, however, the use of immunosuppressant in patients with hepatitis B infection ha...

Therapeutic controversies: tumor necrosis factor α inhibitors in ankylosing spondylitis.
https://doi.org/10.1016/j.rdc.2012.08.004
Rheumatic Diseases Clinics of North America; Song IH, Maksymowych WP

Oct 22nd, 2012 - Tumor necrosis factor α inhibitors (TNF blockers) have revolutionized the treatment of patients with anklyosing spondylitis. Despite clinical efficacy, there are questions and controversies treating rheumatologists face, which this review discusse...

see more →

Clinicaltrials.gov  1 results

Prevalence and Clinical Course of Chronic Hep B Infection in IBD and Rheumatologic Disease
https://clinicaltrials.gov/ct2/show/NCT02128503

Apr 24th, 2017 - The incidence of inflammatory bowel disease (IBD) has been increasing in Hong Kong. The management of inflammatory bowel disease involved the use of immunosuppressant, however, the use of immunosuppressant in patients with hepatitis B infection ha...

see more →

News  1 results

Oral JAK Inhibitor Promising in Ankylosing Spondylitis
https://www.medscape.com/viewarticle/864608

Jun 8th, 2016 - LONDON, United Kingdom — The oral Janus kinase (JAK) inhibitor tofacitinib (Xeljanz, Pfizer) might be a new option for patients with ankylosing spondylitis, according to results from a new phase 2 study. "This is the first study to demonstrate the...

see more →